Literature DB >> 12662069

Total synthesis of (+)-astrophylline.

Marco Schaudt1, Siegfried Blechert.   

Abstract

The first total synthesis of (+)-astrophylline (2) has been achieved, starting from readily available enantiomerically pure (+)-(1R,4S)-4-hydroxycyclopent-2-enyl acetate (11). A novel ruthenium-catalyzed ring-closing ring-opening ring-closing metathesis of carbocyclic olefins of general type 5 was the key step, providing the stereochemically well-defined bis-piperidyl skeleton of the target molecule. A [2,3]-Wittig-Still rearrangement of 9 was also employed as the critical transformation in the stereocontrolled generation of the 1,2-trans configuration of the cyclopentene intermediate 6c. Our early synthetic efforts toward 1,2-trans cyclopentene derivatives of type 6, as well as the synthetic pathway to an optimized 13-step total synthesis of 2 (12% overall yield), are reported.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12662069     DOI: 10.1021/jo026803h

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  3 in total

1.  Enhancing the Antiviral Efficacy of RNA-Dependent RNA Polymerase Inhibition by Combination with Modulators of Pyrimidine Metabolism.

Authors:  Qi Liu; Amita Gupta; Ayse Okesli-Armlovich; Wenjie Qiao; Curt R Fischer; Mark Smith; Jan E Carette; Michael C Bassik; Chaitan Khosla
Journal:  Cell Chem Biol       Date:  2020-05-21       Impact factor: 8.116

2.  Stereoselective, nitro-Mannich/lactamisation cascades for the direct synthesis of heavily decorated 5-nitropiperidin-2-ones and related heterocycles.

Authors:  Pavol Jakubec; Dane M Cockfield; Madeleine Helliwell; James Raftery; Darren J Dixon
Journal:  Beilstein J Org Chem       Date:  2012-04-16       Impact factor: 2.883

3.  Desymmetrization of 7-azabicycloalkenes by tandem olefin metathesis for the preparation of natural product scaffolds.

Authors:  Wolfgang Maison; Marina Büchert; Nina Deppermann
Journal:  Beilstein J Org Chem       Date:  2007-12-18       Impact factor: 2.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.